Patent number: 12594227
Abstract: A tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-QTAV-Z wherein Q denotes Glutamine, T denotes Threonine, A denotes Alanine and V denotes Valine, at the N-terminal end, U is independently selected from the group consisting of octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), biotinoyl, elaidoyl, oleoyle, lipoyle, at the C-terminal end, Z is selected from the group consisting of OH, O R1, NHR1 or NR1R2, R1 and R2 are independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclical, polycyclic, unsaturated, hydroxylates, carbonylated, phosphorylated and/or sulphurous, said groups comprising from 1 to 24 carbon atoms and being capable of including one or more heteroatoms O, S and/or N.
Type:
Grant
Filed:
November 16, 2021
Date of Patent:
April 7, 2026
Assignee:
THE BOOTS COMPANY PLC
Inventors:
Michael David Bell, Eleanor Jane Bradley, Yegor Doush, Michael John Sherratt, Matiss Ozols, Alexander Eckersley
Publication number: 20230414476
Abstract: According to the present invention, there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, having the amino acid sequence U-(SEQ ID No: 1)-Z, U-(SEQ ID No: 2)-Z, U-(SEQ ID No: 3)-Z, U-(SEQ ID No: 4)-Z, U-(SEQ ID No: 5)-Z, U-(SEQ ID No: 6)-Z, U-(SEQ ID No: 7)-Z, U-(SEQ ID No: 8)-Z, U-(SEQ ID No: 9)-Z, U-(SEQ ID No: 11)-Z, U-(SEQ ID No: 12)-Z, U-(SEQ ID No: 13)-Z, U-(SEQ ID No: 14)-Z, U-(SEQ ID No: 15)-Z, U-(SEQ ID No: 16)-Z, U-(SEQ ID No: 17)-Z, U-(SEQ ID No: 18)-Z, U-(SEQ ID No: 19)-Z, U-(SEQ ID No: 20)-Z, U-(SEQ ID No: 21)-Z, U-(SEQ ID No: 22)-Z, U-(SEQ ID No: 23)-Z, U-(SEQ ID No: 24)-Z, U-(SEQ ID No: 25)-Z, U-(SEQ ID No: 26)-Z, U-(SEQ ID No: 27)-Z, U-(SEQ ID No: 28)-Z, and U-(SEQ ID No: 29)-Z.
Type:
Application
Filed:
November 16, 2021
Publication date:
December 28, 2023
Inventors:
Michael David Bell, Eleanor Jane Bradley, Yegor Doush, Michael John Sherratt, Matiss Oaols, Alexander Eckersley
Publication number: 20230414477
Abstract: A tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-QTAV-Z wherein Q denotes Glutamine, T denotes Threonine, A denotes Alanine and V denotes Valine, at the N-terminal end, U is independently selected from the group consisting of octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), biotinoyl, elaidoyl, oleoyle, lipoyle, at the C-terminal end, Z is selected from the group consisting of OH, O R1, NHR1 or NR1R2, R1 and R2 are independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclical, polycyclic, unsaturated, hydroxylates, carbonylated, phosphorylated and/or sulphurous, said groups comprising from 1 to 24 carbon atoms and being capable of including one or more heteroatoms O, S and/or N.
Type:
Application
Filed:
November 16, 2021
Publication date:
December 28, 2023
Inventors:
Michael David Bell, Eleanor Jane Bradley, Yegor Doush, Michael John Sherratt, Matiss OZOLS, Alexander Eckersley
Publication number: 20230416304
Abstract: According to the present invention, there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-LSXX-Z wherein L is used to denote amino acid Leucine and S is used to denote Serine, as per the internationally recognised single letter code for amino acids, X denotes an amino acid selected from the group consisting of Valine (V), Aspartic acid (D), Proline (P), Glycine (G) and mixtures thereof, at the N-terminal end, U is selected from the group consisting of H, —CO—R1, —SO2—R1 or a biotinyl group, at the C-terminal end, Z is selected from the group consisting of OH, O R1, NHR1 or NR1R2; wherein if U is H then Z cannot be OH and R1 and R2 are independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclical, polycyclic, unsaturated, hydroxylates, carbonylated, phosphorylated and/or sulphur
Type:
Application
Filed:
November 16, 2021
Publication date:
December 28, 2023
Inventors:
Michael David Bell, Eleanor Jane Bradley, Yegor Doush, Michael John Sherratt, Matiss Ozols, Alexander Eckersley
Patent number: 10335357
Abstract: A water-in-oil emulsion comprising less than 60% water, and wherein said emulsion comprises an oil phase and a water phase, and wherein the water phase comprises a dipeptide selected from the group consisting of acetyl dipeptide (1) cetyl ester, acetyl dipeptide (3) aminohexanoate, azelaoyl bisdipeptide (10), coumaroyl dipeptide (3), dicetyl dipeptide (9), dipeptide diamino butyroyl benzylamide diacetate, dipeptide (1), dipeptide (10), dipeptide (11), dipeptide (12), dipeptide (15), dipeptide (16), dipeptide (17), dipeptide (18), dipeptide (19), dipeptide (2), dipeptide (20), dipeptide (3), dipeptide (4), dipeptide (5), dipeptide (6), dipeptide (7), dipeptide (8), dipeptide (8) HCL, dipeptide (9), hexanoyl dipeptide (3) norleucine acetate, methyl undecylenoyl dipeptide (16), nicotinoyl dipeptide (22), nicotinoyl dipeptide (23), nicotinoyl dipeptide (24), nicotinoyl dipeptide (26), oleoyl dipeptide (15), palmitoyl dipeptide (10), palmitoyl dipeptide (13), palmitoyl dipeptidel (7), palmitoyl dipeptide (5) diami
Type:
Grant
Filed:
May 15, 2014
Date of Patent:
July 2, 2019
Assignee:
THE BOOTS COMPANY PLC
Inventors:
Paul James Tomlinson, Mark Johnson, Michael David Bell